Extract
A Covid-19 vaccine candidate being developed by GlaxoSmithKline and Sanofi delivers a strong immune response, preliminary trial results have shown.
The companies said the study of the vaccine as a single booster dose showed an increase in neutralising antibodies, regardless of the primary vaccine received such as Pfizer-BioNTech or AstraZeneca, and for all age groups tested.
“This is the most comprehensive booster trial to date to explore boosting across different vaccine technologies used for primary vaccination”, they said.
Roger Connor, president of vaccines at GSK, said: “As the pandemic threat continues with the current dominant Delta variant and Omicron rapidly gaining ground, booster vaccines will continue to be needed to help protect people over time.”